Pharma | Pharmaceutical industry | News | Healthcare

After Tavapadon Success in Phase 3 Prakinson's Disease Trial, Emraclidine Fails In Schizophrenia | Shares Tumbles by 12% | iPharmaCenter

AbbVie's recent clinical trial results for emraclidine and tavapadon reflect a mixed outcome in their efforts to advance neurological...

Alexion's Koselugo Shows Improved Objective Response Rate in Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Koselugo (selumetinib) Shows Notable Improvement in Objective Response Rate Versus Placebo for Adults with Neurofibromatosis Type 1 and...

Best selling immunology drugs by revenues | Top immunology drugs | 2024 | iPharmaCenter

Dupixent - $6.8 billion Stelara - $5.3 billion Humira - $ 5.0 billion Skyrizi - $4.7 billion Cosentyx - $2.9 billion Entyvio - $2.9...

Top selling cancer drugs of 2024 | Best selling cancer drugs | Top cancer drugs by revenues in 2024 | iPharmaCenter

Keytruda - $7.3 billion Darzalex - $5.6 billion Opdivo - $4.5 billion Tagrisso - $3.2 billion Revlimid - $3.0 billion Verzenio - $2.4...

Top pharmaceutical companies by revenues in 2024 | Biggest Pharma of 2024 | Top Pharma profits | iPharmaCenter

TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2024 Sl No Company Q1 Q2 Q3 Total Best selling products 1 JOHNSON AND JOHNSON $21.8 $43.8...

Expected | Best selling drugs of 2024 | Top selling drugs of 2024 | iPharmaCenter

1. Keytruda: Revolutionizing Cancer Care Keytruda (pembrolizumab), an immunotherapy drug by Merck, has transformed cancer treatment....

LEQEMBI (Lecanemab) Receives Approval in Israel for Treating Alzheimer's Disease | iPharmaCenter

Eisai and Biogen have announced that their humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody, LEQEMBI (lecanemab),...

Pharmaceutical deals | Acquistions | 2024 | iPharmaCenter

Overview NovoNordisk Collaboration with Omega Therapeutics and Cellarity Novartis and Voyager Collaboration to Develop Gene Therapies for...

Lilly's Tirzepatide Shows Promise in MASH Treatment, Achieves Notable Results in Phase 2 Study | iPharmaCenter

Eli Lilly has revealed promising results from the SYNERGY-NASH study, a phase 2 clinical trial assessing tirzepatide's efficacy in...

Top selling drugs of 2024 | Best selling drugs of 2024 | iPharmaCenter

1. Keytruda (Pembrolizumab) Approved for: Keytruda is approved for treating various types of cancer, including melanoma, non-small cell...

European Commission Approves Opdivo with Cisplatin and Gemcitabine for First-Line Treatment of Advanced Urothelial Carcinoma | iPharmaCenter

The European Commission (EC) has granted approval for Opdivo (nivolumab) in combination with cisplatin and gemcitabine for first-line...

Merck Announces Success in Phase 3 KEYNOTE-522 Trial for High-Risk Early-Stage Triple Negative Breast Cancer (TNBC) | iPharmaCenter

KEYTRUDA (pembrolizumab) achieves milestone as first immunotherapy to significantly enhance overall survival in high-risk early-stage...

Australia Healthcare News | Media | Updates

New medications, Jemperli and Korsuva will be available for endometrial cancer and chronic kidney disease For women facing advanced or...

19th January, 2024 Tirzepatide Recommended alongside dietary adjustments and physical activity to enhance blood sugar management in...

CMS aims to address kidney transplant issues with Enhanced Access to Organ Transplant initiative | iPharmaCenter

The Health and Human Services Department in the United States, administered by the Centers for Medicare & Medicaid Services (CMS), is...

HHS Unveils Fresh Data Revealing Over 10 Million Medicare Beneficiaries Received Complimentary Vaccines Under President's Initiative to Curb Inflation | US Healthcare News | iPharmaCenter

More than 10 million individuals enrolled in Medicare Part D received no-cost vaccines in 2023 due to the Inflation Reduction Act, a...

Top 10 best selling cancer drugs in 2023 | Top cancer drug makers | iPharmaCenter

1. KEYTRUDA Revenues in 2023: $25 billion Company: Merck & Co. Approved Indications: Keytruda is approved for several cancer types:...

World Congress of Nephrology (WCN) | News | Updates | 2024 | iPharmaCenter

Novartis presented new data of Fabhalta showing improvement in proteinuria in patients with IgA nephropathy Novartis revealed new data...

Giant cell arteritis | Rinvoq | News | Media | iPharmaCenter

AbbVie presented positive data of Rinvoq in patients with giant cell arteritis AbbVie released positive outcomes from the SELECT-GCA...

FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

April 02, 2024 Abbott Secures FDA Nod for Triclip, Novel Tool for Mending Faulty Tricuspid Heart Valve Abbott revealed that the U.S. Food...

Zeposia failed to meet the efficacy endpoints in patients with Crohn's disease Bristol Myers Squibb has provided an update on the...

Japan Drug Approvals | March 2024 | PMDA | MHLW Updates | iPharmaCenter

Approval of Truqap plus Faslodex Granted in Japan for Patients Dealing with Advanced Hormone Receptor-Positive Breast Cancer Beyfortus...

FDA approved Orchard Therapeutics' Lenmeldy for juvenile metachromatic leukodystrophy | FDA Approvals | News | iPharmaCenter

The U.S. Food and Drug Administration has given its approval for Lenmeldy (atidarsagene autotemcel), marking the first-ever...

CHMP Positive Opinions | February | 2024 | iPharmaCenter

Voydeya Received CHMP Position Opinion for Residual Haemolytic Anaemia for PNH The CHMP of the European Medicines Agency (EMA) has...

BEST SELLING DIABETES MELLITUS DRUGS IN 2023 Ozempic - $13.8 billion Trulicity - $7.1 billion Farxiga - $6.0 billion Mounjaro - $5.2...

Dupixent approved for chronic spontaneous urticaria Japan became the first country to approve Dupixent for chronic spontaneous urticaria...

Express-Scripts included the use of interchangeable insulin biosimilars, which aims to improve cost savings. Express-Scripts included the...

Top pharma companies by revenues in 2023| Best Selling Drugs of 2023 |Top 20 pharma companies | iPharmaCenter

TOP PHARMACEUTICAL COMPANIES BY REVENUES 2023 Merck revenues exclude animal health revenues 1. JOHNSON AND JOHNSON Q1 REVENUES Johnson...

December 27, 2023 Lilly completed the acquisition of POINT Biopharma and entered the race to develop novel radiopharmaceuticals for...

Top CMS Pharmaceutical Expenditures: Analyzing High-Expenditure Medications

DRUGS ON WHICH CMS SPENT THE MOST IN 2021 Also read: Top pharma companies by revenues in 2023 1. Eliquis (Apixaban): Indications: Eliquis...

Best selling drugs of 2023 | Top 10 drugs by revenues | Best selling pharmaceuticals | iPharmaCenter

BEST SELLING DRUGS OF 2023 | TOP 10 DRUGS BY REVENUES Also read: Top pharma companies by revenues in 2023 Top pharmaceutical companies by...

Depression | How common is depression? How to deal with depression? | iPharmaCenter

Major depression is a significant global health concern, ranking second leading cause of disability worldwide. The international...

Radioligand therapy news | Updates | iPharmaCenter

October 03, 2023 Eli Lilly to enter the radioligand therapy field with the acquisition of POINT Biopharma. Eli Lilly and POINT Biopharma...

October 30, 2023 Novartis' Atrasentan Shows Promise in Phase 3 Study for IgA Nephropathy Treatment Novartis reported encouraging results...

Cancer News | Cancer Updates | Recent updates in cancer treatment, diagnosis | iPharmaCenter

September 29, 2023 The FDA authorized DNA test to detect various cancers The Food and Drug Administration (FDA) authorized first-ever...

Top selling immunology drugs | Top 10 immunology drugs by revenues | iPharmaCenter

TOP IMMUNOLOGY DRUGS BY REVENUES IN 2022 Humira (Adalimumab): In the realm of immunology drugs, one name stands out as a global success...

Chronic rhinosinusitis with nasal polyps | News | Updates | iPharmaCenter

In Japan, the regulatory submission for Nucala (mepolizumab) for chronic rhinosinusitis with nasal polyps was accepted for review by the...

PCSK9 inhibitors | Heart Failure News | Updates | iPharmaCenter

Merck has commenced the Phase 3 clinical program, named CORALreef, for MK-0616. MK-0616 is an investigational oral proprotein convertase...

Chronic spontaneous urticaria | News | Updates |

Novartis has achieved encouraging results in the Phase III trials of remibrutinib, showcasing its effectiveness in managing symptoms of...

10 Most Expensive Drugs | 2023 | Pharmaceuticals | iPharmaCenter

MOST EXPENSIVE PHARMACEUTICALS APPROVED BY THE US FDA 1. Hemgenix (etranacogene dezaparvovec) Cost of therapy: $3.5 million Manufacturer:...

Multiple Sclerosis | News | Blogs | Updates | 2023

Roche reported the Phase II FENopta study of fenebrutinib in adult patients with relapsing forms of multiple sclerosis (RMC). The drug...

December 12, 2022 After Sanofi failed to acquire, Amgen announced its plan to acquire Horizon Therapeutics. Amgen announced that it has...

How is AbbVie bracing for the impact of Humira’s biosimilars? | iPharmaCenter

AbbVie’s multibillion blockbuster Humira has been the best-selling product in the industry for several years. It generated $21.2 billion...

TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2022

REVENUES OF TOP BIOPHARMACEUTICAL COMPANIES - 2022 1 CHF = 1.01 USD, 1 GBP = 1.16USD; 1EUR= 0.99 USD; 1DKK = 0.13 USD; 1 JPY = 0.0075 USD...

Top-selling cancer drugs | 2022 | 2023 | Best cancer products | iPharmaCenter

CLICK HERE TO CHECK TOP PHARMACEUTICALS BY REVENUES IN 2023 1. Keytruda Revenues: $20.9 billion Indications: Advanced non-small cell lung...

Top 5 drug launches in 2023 that has potential to be blockbusters | iPharmaCenter

FIVE DRUG LAUNCHES IN 2023 THAT HAS POTENTIAL TO BECOME BLOCKBUSTERS Peak revenues are collected from different sources SRP-9001 Patients...

Expected best selling drugs of 2023

ANTICIPATED/EXPECTED BEST SELLING PRODUCTS OF 2023 CLICK HERE TO CHECK TOP PHARMACEUTICALS BY REVENUES IN 2023 Evaluate has published the...

GSK maintains the top place in the Access to Medicines rating in 2022; J&J and AZ followed the list The 2022 Access to Medicine Index was...

Multiple Myeloma | News | Blogs | FDA and EMA approvals | Updates on clinical guidelines

November 07, 2022 Blenrep failed to demonstrate superior PFS versus PomDex in RRMM patients GSK announced that Blenrep (belantamab...

Merck and Moderna agreed to develop and commercialize a cancer vaccine | iPharmaCenter

Merck and Moderna have announced that Merck has exercised its option to collaborate and commercialize the cancer vaccine. The companies...